News | March 12, 2015

KLAS Report Finds Siemens Preferred Vendor for Provider Partnership Agreements

The company was recognized as the preferred standard in CT, MR, interventional X-ray and molecular imaging

Siemens, KLAS, preferred vendor, partnership agreements

March 12, 2015 — In a recent survey by the KLAS research firm, Siemens Healthcare was the designated vendor for healthcare providers in 47 percent of current partnership agreements. Moreover, the survey also found that Siemens is the vendor that more executives from the nation’s largest health systems would select over any other company as their first choice for a future partner.

Facing reductions in medical imaging reimbursement, healthcare providers rely increasingly on partnerships with medical imaging equipment manufacturers – which involve the provider using the same vendor across multiple imaging modalities – to help them realize additional sources of value.

Of the 79 surveyed healthcare executives — who represent systems with an average of 2,400 beds — 34 percent identified Siemens as their first-time choice for a partner; that percentage was substantially higher than any other vendor cited in the 2014 KLAS CxO Perceptions Report, entitled “Medical Imaging 2014: Provider Executives Weigh In on Imaging Partnerships.” These healthcare executives also cited Siemens as one of the providers they would be least likely to avoid (14 percent). Additionally, the KLAS report identified Siemens as having the fewest number of dissolved partnerships with healthcare systems.

The surveyed executives praised Siemens’ reliability and cited the company as offering the most innovative medical imaging technology, identifying Siemens as the “preferred standard” in computed tomography (CT), magnetic resonance (MR), interventional X-ray, and molecular imaging.

For more information: www.klasresearch.com

Related Content

360 Photos | Angiography | May 17, 2019
This is a view inside one of the 11 cath labs at ...
360 Photos | Magnetic Resonance Imaging (MRI) | May 17, 2019
This is a dedicated cardiac Siemens 1.5T MRI system installed at the Baylor Scott White Heart Hospital in Dallas.
New Study Evaluates Head CT Examinations and Patient Complexity
News | Neuro Imaging | May 17, 2019
Computed tomography (CT) of the head uses special X-ray equipment to help assess head injuries, dizziness and other...
Miami Cardiac and Vascular Institute Implements Philips Ingenia Ambition X 1.5T MRI
News | Magnetic Resonance Imaging (MRI) | May 17, 2019
Miami Cardiac & Vascular Institute announced the implementation of Philips’ Ingenia Ambition X 1.5T MR, the world’s...
Managing Architectural Distortion on Mammography Based on MR Enhancement
News | Mammography | May 15, 2019
High negative predictive values (NPV) in mammography architectural distortion (AD) without ultrasonographic (US)...
FDA Clears Aidoc's AI Solution for Flagging Pulmonary Embolism
Technology | Artificial Intelligence | May 15, 2019
Artificial intelligence (AI) solutions provider Aidoc has been granted U.S. Food and Drug Administration (FDA)...
Netherlands Hospital to Install State-of-the-Art MRI Ablation Center
News | Magnetic Resonance Imaging (MRI) | May 13, 2019
Imricor announced the signing of a commercial agreement with the Haga Hospital in The Hague, Netherlands to outfit a...
Screening MRI Detects BI-RADS 3 Breast Cancer in High-risk Patients
News | MRI Breast | May 09, 2019
When appropriate, short-interval follow-up magnetic resonance imaging (MRI) can be used to identify early-stage breast...
Clinical Trial Explores Opening Blood-Brain Barrier in Fight Against Alzheimer's

Vibhor Krishna, M.D., (right) fits David Shorr with a helmet-like device used in a new clinical trial for Alzheimer’s disease at The Ohio State University Wexner Medical Center. The device uses MRI-guided imaging to deliver focused ultrasound to specific areas of the brain to open the blood-brain barrier. Image courtesy of Ohio State University Wexner Medical Center.

News | Focused Ultrasound Therapy | May 09, 2019
May 9, 2019 — A new clinical trial at The Ohio State University Wexner Medical Center and two other sites is testing